Biosimilar insulins – What a clinician needs to know?

As the first biologics produced by recombinant deoxyribonucleic acid (DNA) technology were approved in the late 1980s and consequently the exclusive marketing rights of most of these biological medicinal products have expired or will expire very shortly, it is quite evident that biosimilars are bein...

Full description

Bibliographic Details
Main Authors: Sujoy Ghosh, Saptarshi Bose, Sandeep Gowda, Pradip Mukhopadhyay
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=4;spage=400;epage=406;aulast=Ghosh